Advanced Biomed (ADVB) Liabilities and Shareholders Equity (2024 - 2026)

Advanced Biomed has disclosed Liabilities and Shareholders Equity across 3 years of filings, most recently posting $10.6 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $10.6 million, up 28.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $41.5 million (up 140.31% YoY), and the FY2025 annual result was $13.7 million, up 207.56% from the prior year.
• Liabilities and Shareholders Equity came in at $10.6 million for Q1 2026 at Advanced Biomed, down from $10.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $13.7 million in Q2 2025 to a low of $4.5 million in Q2 2024.
• The 3-year median for Liabilities and Shareholders Equity is $8.3 million (2025), against an average of $8.4 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 207.56% in 2025 and rose 28.46% in 2026, its largest moves.
• Advanced Biomed's Liabilities and Shareholders Equity stood at $4.5 million in 2024, then jumped by 140.9% to $10.9 million in 2025, then fell by 1.88% to $10.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $10.6 million (Q1 2026), $10.9 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.